CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Significant Drop in Short Interest

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 3,620 shares, a decline of 43.2% from the August 31st total of 6,370 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 11,046 shares, the days-to-cover ratio is currently 0.3 days.

CytoMed Therapeutics Price Performance

CytoMed Therapeutics stock traded down $0.05 during trading on Wednesday, reaching $0.84. The company had a trading volume of 13,004 shares, compared to its average volume of 13,804. CytoMed Therapeutics has a 12-month low of $0.68 and a 12-month high of $3.68. The stock’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $0.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.

CytoMed Therapeutics (NASDAQ:GDTC) last released its quarterly earnings data on Wednesday, September 30th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.06 million for the quarter.

Analyst Ratings Changes

Several brokerages have commented on GDTC. Fundamental Research set a $4.16 price objective on CytoMed Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CytoMed Therapeutics has an average rating of “Hold” and a consensus target price of $4.16.

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.